Pfizer shells out nearly $60M to resolve Nurtec kickback claims inherited in Biohaven buyout
27th January 2025 Uncategorised 0Pfizer—which purchased Biohaven for $11.6 billion in 2022—is committing more than $59.7 million to resolve kickback allegations tied to its neuroscience subsidiary’s migraine med Nurtec. More: Pfizer shells out nearly M to resolve Nurtec kickback claims inherited in Biohaven buyout
read more